// App-Quantinova.ai

PO‐036 : Interim analysis of the TARGET UK study: real‐world use of tyrosine kinase inhibitors in UK patients with chronic myeloid leukaemia

Researchers

Presenter

  • D Milojkovic

Principal Investigators

  • R Clark

  • J Byrne

  • M Raghavan

  • M Drummond

  • F Wandroo

  • S Ali

  • B Huntly

  • J Ryan

  • S Sanz

  • P Robson

  • A Goringe

  • G Campbell

  • B Austen

  • F Willis

  • NCP Cross

  • A Mead

Medical Centers

  • Imperial College Healthcare NHS Trust, London,

  • Royal Liverpool and Broardgreen University Hospital NHS Trust, Liverpool, United Kingdom

  • Nottingham University Hospitals NHS Trust, Nottingham,

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • NHS Greater Glasgow and Clyde, Glasgow, UK

  • Sandwell and West Birmingham Hospital NHS Trust, Birmingham, United Kingdom

  • Hull and East Yorkshire Hospitals NHS Trust

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Novartis Pharmaceuticals UK Limited

  • Gloucestershire Hospitals NHS Foundation Trust,Gloucester, UK

  • Cardiff and Vale University Health Board, Cardiff,

  • Colchester Hospital University NHS Foundation Trust, Essex

  • Taunton and Somerset NHS Foundation Trust

  • St Georges University Hospitals NHS Foundation Trust, London, UK

  • University of Southampton, Southampton, UK

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

Drug/Treatment

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved